Generated by AI
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. GeoVax’s current portfolio centers on human vaccine candidates that address serious viral threats, including COVID-19, mpox, smallpox, and other high-consequence infectious diseases, alongside oncology programs aimed at difficult-to-treat solid tumors. The company’s pipeline includes vaccine and therapy development built on proprietary platform technologies designed to support immune responses across preventive and therapeutic settings. Its work spans infectious disease prevention, biodefense-related vaccines, and cancer immunotherapy, making GeoVax Labs a specialized player in the biotechnology market with an emphasis on unmet medical needs.
Website1955 Lake Park Drive
Smyrna, GA, 30080
United States
The latest articles about GOVX.
Summary of Nov 11's posts. Generated by AI.
Summary of May 26's posts. Generated by AI.
Presentation to Highlight Single-Dose MVA and Continuous Cell-Line MVA Manufacturing Innovations ATLANTA, GA - October 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunothe...
Summary of Oct 5's posts. Generated by AI.
Investors talking about GOVX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.